Document is current
Any future updates will be listed below
-
Authors
Ulpiano, Cristiana
Salvador, William
Franchi-Mendes, Teresa
Huang, Min-Chang
Lin, Yee-Hsien
Lin, Han-Tse
Rodrigues, Carlos A. V.
Fernandes-Platzgummer, Ana
Cabral, Joaquim M. S.
Monteiro, Gabriel A.
da Silva, Cláudia L. https://orcid.org/0000-0002-1091-7651
-
Funding
Funding for this research was provided by:
Fundação para a Ciência e a Tecnologia (UIDB/04565/2020 and UIDP/04565/2020, PTDC/EQU-EQU/31651/2017)
- License Information
-
More Information
Article History
Received: 15 November 2024
Accepted: 11 April 2025
First Online: 24 April 2025
Declarations
:
: For primary cell isolation (MSC(WJ)), human samples were obtained from healthy donors at Hospital São Francisco Xavier, Centro Hospitalar de Lisboa Ocidental (CHLO) after written and informed consent and according to the Directive 2004/23/EC of the European Parliament and of the Council of 31 March 2004 on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells (Portuguese Law 22/2007, June 29). The collaborative project Protocol iBB/SGO-CHLO (iBB-Institute for Bioengineering and Biosciences of Instituto Superior Técnico and Department of Gynecology and Obstetrics (SGO, Serviço de Ginecologia e Obstetrícia) of CHLO) was approved on May 2012 by the Ethics Committee of CHLO - nº1277.The cell lines used in this study are commercially available and were provided in accordance with the vendors’ compliance policies. HUVECs were obtained from Lonza and the breast cancer cell lines MDA-MB-231 and MCF-7 were obtained from ATCC.
: N/A.
: M-CH, Y-HL and H-TL had compensated employment at AventaCell BioMedical Corp. No potential conflicts of interest were disclosed by the other authors.
